3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Endometrial Neoplasms
2
Uterine Prolapse
1
Uterine Cervical Neoplasms
1
Precancerous Conditions
1
Ovarian Neoplasms
1
Menstruation Disturbances
1
Leiomyoma
1
Endometriosis
1
Carcinoma, Endometrioid
1
Adenomyosis
1
Interventions
Bevacizumab
35
Paclitaxel
31
Carboplatin
24
pembrolizumab
23
Specimen Handling
21
Magnetic Resonance Spectroscopy
19
Gemcitabine
18
olaparib
16
liposomal doxorubicin
16
Cyclophosphamide
15
fludarabine
12
Topotecan
12
Biopsy
12
niraparib
11
Cisplatin
10
Taxes
8
Nivolumab
8
Immunoglobulin G
8
Fulvestrant
8
Disulfides
8
Doxorubicin
7
aldesleukin
6
Surveys and Questionnaires
6
palbociclib
5
Oxaliplatin
5
Fluorouracil
5
trastuzumab deruxtecan
4
oregovomab
4
mirvetuximab soravtansine
4
X-Rays
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Hysterectomy
×
90 days
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled